AACR 2012: AV-203, a Humanized ERBB3 Inhibitory Antibody Inhibits Ligand-Dependent and Ligand-Independent ERBB3 Signaling in vitro and in vivo

Click Here To View Our ASCO Poster:

TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)